| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $2,353,134 | 26 | 100 |
| Wuchterl Donald A. | director | 0 | $0 | 1 | $30,147 | $-30,147 |
| Crombez Eric | director | 0 | $0 | 1 | $32,683 | $-32,683 |
| Charles Faith L. | director | 0 | $0 | 1 | $62,879 | $-62,879 |
| Silverstein Christine Berni | director | 0 | $0 | 1 | $76,669 | $-76,669 |
| O'Malley Brendan M. | SVP, General Counsel | 0 | $0 | 4 | $227,082 | $-227,082 |
| Alvino Mark | director | 0 | $0 | 6 | $247,956 | $-247,956 |
| Vazzano Joseph Walter | Chief Financial Officer | 0 | $0 | 5 | $438,156 | $-438,156 |
| Seshadri Vishwas | Chief Executive Officer | 0 | $0 | 7 | $1.24M | $-1.24M |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Over the last 12 months, insiders at Abeona Therapeutics Inc. have bought $0 and sold $2.35M worth of Abeona Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Abeona Therapeutics Inc. have bought $134,796 and sold $1.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,000 shares for transaction amount of $51,799 was made by Alland Leila (director) on 2024‑05‑16.
| 2025-12-29 | Sale | Seshadri Vishwas | Chief Executive Officer | 25,000 0.0487% | $5.31 | $132,740 | -3.54% | |
| 2025-11-13 | Sale | Alvino Mark | director | 15,000 0.0306% | $4.74 | $71,168 | +12.69% | |
| 2025-10-16 | Sale | Seshadri Vishwas | Chief Executive Officer | 249 0.0005% | $5.49 | $1,366 | -7.13% | |
| 2025-09-30 | Sale | Seshadri Vishwas | Chief Executive Officer | 25,000 0.0484% | $5.24 | $130,930 | -2.46% | |
| 2025-09-29 | Sale | Seshadri Vishwas | Chief Executive Officer | 19,274 0.038% | $5.39 | $103,954 | -3.38% | |
| 2025-09-29 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 9,035 0.0178% | $5.39 | $48,730 | -3.38% | |
| 2025-09-29 | Sale | O'Malley Brendan M. | SVP, Chief Legal Officer | 9,366 0.0185% | $5.39 | $50,516 | -3.38% | |
| 2025-09-22 | Sale | O'Malley Brendan M. | SVP, Chief Legal Officer | 688 0.0013% | $5.43 | $3,736 | -5.20% | |
| 2025-08-15 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 15,000 0.0303% | $7.36 | $110,358 | -25.18% | |
| 2025-08-14 | Sale | Crombez Eric | director | 4,718 0.0088% | $6.93 | $32,683 | -26.14% | |
| 2025-07-22 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 1,502 0.003% | $6.64 | $9,975 | -17.02% | |
| 2025-07-09 | Sale | Seshadri Vishwas | Chief Executive Officer | 69,420 0.1363% | $5.86 | $406,503 | -6.69% | |
| 2025-07-09 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 25,411 0.0499% | $5.86 | $148,799 | -6.69% | |
| 2025-07-09 | Sale | O'Malley Brendan M. | SVP, Chief Legal Officer | 17,428 0.0342% | $5.86 | $102,053 | -6.69% | |
| 2025-07-09 | Sale | Charles Faith L. | director | 10,738 0.0211% | $5.86 | $62,879 | -6.69% | |
| 2025-07-09 | Sale | Silverstein Christine Berni | director | 13,093 0.0257% | $5.86 | $76,669 | -6.69% | |
| 2025-07-09 | Sale | Alvino Mark | director | 13,093 0.0257% | $5.86 | $76,669 | -6.69% | |
| 2025-07-08 | Sale | Wuchterl Donald A. | director | 5,176 0.0101% | $5.82 | $30,147 | -6.85% | |
| 2025-06-06 | Sale | Seshadri Vishwas | Chief Executive Officer | 50,676 0.0994% | $6.76 | $342,570 | -18.03% | |
| 2025-06-06 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 17,795 0.0349% | $6.76 | $120,294 | -18.03% |
| Seshadri Vishwas | Chief Executive Officer | 1164818 2.1495% | $6.12M | 3 | 7 | +40.3% |
| Vazzano Joseph Walter | Chief Financial Officer | 453631 0.8371% | $2.38M | 3 | 5 | +24.48% |
| O'Malley Brendan M. | SVP, Chief Legal Officer | 350763 0.6473% | $1.84M | 4 | 9 | +20.67% |
| Wuchterl Donald A. | director | 145436 0.2684% | $763,539.00 | 0 | 1 | |
| Charles Faith L. | director | 139094 0.2567% | $730,243.50 | 1 | 2 | +63.5% |
| Silverstein Christine Berni | director | 120479 0.2223% | $632,514.75 | 0 | 3 | |
| Alvino Mark | director | 62252 0.1149% | $326,823.00 | 0 | 12 | |
| Crombez Eric | director | 42427 0.0783% | $222,741.75 | 0 | 1 | |
| SCO CAPITAL PARTNERS LLC | 11079292 20.4448% | $58.17M | 0 | 11 | ||
| Ayer Capital Management, LP | 10 percent owner | 2413163 4.453% | $12.67M | 0 | 4 | |
| CARR EDWARD | Chief Financial Officer | 400169 0.7384% | $2.1M | 0 | 4 | |
| Ahn Mark J | director | 343182 0.6333% | $1.8M | 2 | 0 | <0.0001% |
| Rouhandeh Steven H | 315042 0.5814% | $1.65M | 1 | 0 | +20.49% | |
| FEINBERG LARRY N | 10 percent owner | 296483 0.5471% | $1.56M | 5 | 11 | |
| Buono Stefano | director | 270000 0.4982% | $1.42M | 3 | 0 | <0.0001% |
| GRAY KERRY P | President and CEO | 183340 0.3383% | $962,535.00 | 2 | 0 | |
| Amoroso Michael | director | 108957 0.2011% | $572,024.25 | 0 | 7 | |
| Alland Leila | director | 82857 0.1529% | $434,999.25 | 1 | 1 | +18.59% |
| MCDADE HERBERT H | director | 81007 0.1495% | $425,286.75 | 0 | 1 | |
| Howell Stephen B. | director | 79494 0.1467% | $417,343.50 | 1 | 0 | <0.0001% |
| Jeffrey B Davis | director | 67858 0.1252% | $356,254.50 | 1 | 0 | +20.49% |
| NOWOTNIK DAVID P | Sr Vice President R&D | 62000 0.1144% | $325,500.00 | 1 | 0 | |
| Meakem John J | director | 45000 0.083% | $236,250.00 | 3 | 0 | |
| Van Duyne Richard B | director | 6000 0.0111% | $31,500.00 | 1 | 0 | <0.0001% |
| Wider Todd | director | 0 0% | $0 | 2 | 8 | <0.0001% |
| Mann Paul Elliot | director | 0 0% | $0 | 0 | 6 |
$26,880,005 | 99 | 5.38% | $253.61M | |
$5,960,789 | 91 | -7.17% | $344.7M | |
$69,137,799 | 70 | 25.27% | $326.54M | |
$87,639,490 | 62 | 18.37% | $278.55M | |
$64,487,106 | 32 | -22.92% | $252.61M | |
$63,049,419 | 31 | 2.87% | $337.52M | |
$79,019,806 | 27 | 7.24% | $267.9M | |
$22,017,898 | 24 | 39.19% | $252.91M | |
Abeona Therapeutics Inc. (ABEO) | $3,668,031 | 23 | 2.05% | $284.5M |
$1,842,003 | 22 | -0.74% | $274.27M | |
$1,447,973 | 17 | 13.95% | $305.69M | |
$65,355,913 | 13 | -3.42% | $318.79M | |
$10,143,329 | 12 | 11.84% | $269.02M | |
$1,346,998 | 7 | 25.06% | $306.57M | |
$17,675,244 | 7 | 92.20% | $320.99M | |
$272,982 | 6 | -28.53% | $310.35M | |
$4,745,999 | 5 | -4.91% | $312.76M | |
$2,720,023 | 3 | -11.76% | $271.85M | |
$136,410 | 2 | -13.40% | $265.63M |
| Increased Positions | 58 | +61.7% | 5M | +13.44% |
| Decreased Positions | 38 | -40.43% | 4M | -11.38% |
| New Positions | 19 | New | 1M | New |
| Sold Out Positions | 14 | Sold Out | 714,373 | Sold Out |
| Total Postitions | 114 | +21.28% | 36M | +2.06% |
| Nantahala Capital Management, Llc | $24,238.00 | 8.45% | 4.56M | +195,000 | +4.46% | 2025-09-30 |
| Blackrock, Inc. | $16,711.00 | 5.83% | 3.15M | +147,996 | +4.93% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $16,185.00 | 5.64% | 3.05M | -25,000 | -0.81% | 2025-09-30 |
| Suvretta Capital Management, Llc | $14,210.00 | 4.96% | 2.68M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $13,821.00 | 4.82% | 2.6M | +95,878 | +3.82% | 2025-09-30 |
| Vivo Capital, Llc | $9,785.00 | 3.41% | 1.84M | 0 | 0% | 2025-09-30 |
| Western Standard Llc | $6,637.00 | 2.32% | 1.25M | -841,641 | -40.24% | 2025-09-30 |
| Geode Capital Management, Llc | $5,985.00 | 2.09% | 1.13M | +21,269 | +1.92% | 2025-09-30 |
| Kennedy Capital Management Llc | $5,580.00 | 1.95% | 1.05M | +378,860 | +56.38% | 2025-09-30 |
| Silverarc Capital Management, Llc | $5,282.00 | 1.84% | 994,754 | +76,856 | +8.37% | 2025-09-30 |